Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Brennan James Decker"'
Autor:
Susan M. Domchek, Kim Anna Reiss, Kate Nathanson, Shannon Bailey, Natalie Danziger, James Thornton, Mark Hartman, Chenming Cui, Lei Yang, Matthew Margolis, Erica Gornstein, Ethan Sokol, Douglas I. Lin, Alexa Betzig Schrock, Douglas A Mata, Christine Vietz, Jeffrey S. Ross, Geoffrey R. Oxnard, Julia Andrea Elvin, Brennan James Decker
Publikováno v:
Journal of Clinical Oncology. 40:5576-5576
5576 Background: Homologous recombination (HR) reversion mutations (REV) are biomarkers for predicting resistance to platinum and PARP inhibitor therapies. The biologic diversity of REV represents a diagnostic challenge. An automated computational ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4abf971280ddb68941c4d95a0c30bc49
https://doi.org/10.1200/jco.2022.40.16_suppl.5576
https://doi.org/10.1200/jco.2022.40.16_suppl.5576
Autor:
Douglas A Mata, Vignesh Shanmugam, Brennan James Decker, Alexa Betzig Schrock, Hanna Tukachinsky, Erik Abraham Williams, Jeffrey S. Ross, Meagan Montesion, Geoffrey R. Oxnard, Jo-Anne Vergilio, Mina L. Xu, Jamal K. Benhamida
Publikováno v:
Journal of Clinical Oncology. 40:e19543-e19543
e19543 Background: LB-based CGP of ctDNA can facilitate the molecular evaluation of lymphoid and plasma cell neoplasms (PCNs), especially when traditional CGP is infeasible due to insufficient tumor in the blood or tissue or when tissue biopsy itself
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e355c35e276ef86b306412882f131bea
https://doi.org/10.1200/jco.2022.40.16_suppl.e19543
https://doi.org/10.1200/jco.2022.40.16_suppl.e19543